8-K: Creative Medical Secures $4.2M Through Warrant Inducement

Creative Medical Technology Holdings, Inc. raised approximately $4.2 million by inducing existing warrant holders to exercise their warrants, issuing new warrants as an incentive.

Summary

• Creative Medical Technology Holdings, Inc. (CELZ) entered into inducement letters with holders of existing warrants to purchase 1,116,136 shares of common stock.
• Holders agreed to exercise their existing warrants at $3.75 per share, generating approximately $4.2 million in gross proceeds for the company.
• In exchange, the company issued new unregistered warrants (Inducement Warrants) to purchase an aggregate of 2,790,340 shares of common stock, representing 250% of the shares from the exercised existing warrants.
• The Inducement Warrants have an initial exercise price of $3.75 per share, subject to reduction to the lowest Volume Weighted Average Price (VWAP) on any trading day during the five trading days commencing on the issue date.
• These new warrants will not be exercisable until shareholder approval is obtained, as required by Nasdaq rules, and will be exercisable for five years thereafter.
• The company also reduced the exercise price of certain warrants issued in May 2022 and December 2021 to $4.73 per share.
• An additional 279,036 shares in the form of Inducement Warrants were issued to an investor who consented to the transaction.
• Roth Capital Partners, LLC acted as financial advisor, receiving an 8% fee on gross proceeds (approximately $336,000) and $40,000 for legal expenses.
• The net proceeds will be used for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The capital raise is a positive for the company's liquidity and operations. However, the significant potential dilution from the new inducement warrants and the reduction in exercise prices for older warrants introduce substantial future shareholder value concerns, balancing the immediate positive impact.

Positives

• Successfully raised approximately $4.2 million in gross proceeds, strengthening the company's working capital and general corporate purposes.
• The inducement offer successfully encouraged existing warrant holders to exercise, providing immediate cash flow.

Negatives

• Significant potential future dilution from the issuance of 2,790,340 new Inducement Warrants, which is 250% of the shares from the exercised existing warrants.
• The exercise price of the new Inducement Warrants is subject to reduction to the lowest VWAP, potentially leading to a lower future exercise price and increased dilution.
• Reduction of exercise prices for warrants issued in May 2022 and December 2021 to $4.73 per share could lead to further dilution if those warrants are exercised.
• Incurred financial advisory fees of 8% of gross proceeds (approximately $336,000) and $40,000 for legal expenses.

Risks

• The Inducement Warrants are not exercisable until shareholder approval is obtained, introducing uncertainty and a potential delay in their exercise.
• The company is prohibited from certain equity sales for 90 days after the closing date, limiting immediate future capital raising flexibility.
• The exercise price of the new warrants can be reduced based on future VWAP, which could result in a lower effective exercise price and greater dilution for existing shareholders.
• Failure to obtain shareholder approval for the issuance of shares underlying the Inducement Warrants could impact the value and exercisability of these new warrants.

Future Outlook

The company plans to file a resale registration statement on Form S-3 for the shares underlying the new Inducement Warrants within 30 days and aims to have it effective within 60-90 days. Shareholder approval is required for the issuance of these shares, and the company commits to using reasonable best efforts to obtain it, including holding a special meeting within 75 days of the issue date and subsequent meetings if necessary. The company also intends to apply for listing of the new warrant shares on Nasdaq and maintain its current listing.

Industry Context

This transaction represents a common strategy for smaller public companies, particularly in the medical technology sector, to raise capital by incentivizing existing warrant holders. It allows the company to secure immediate funding for operations and general corporate purposes without undertaking a traditional public offering, which can be more costly and time-consuming. The issuance of new warrants as an inducement is a way to make the exercise of existing, potentially out-of-the-money or less attractive, warrants more appealing to holders.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the issuance of new warrants and the reduction of exercise prices for older warrants, but benefit from the company's strengthened financial position.
• Warrant Holders (Existing): Incentivized to exercise their warrants for cash, receiving new warrants as a bonus, potentially increasing their future equity stake.
• Warrant Holders (New): Receive new warrants with a five-year term and an exercise price subject to reduction, offering potential upside.

Next Steps

• File a resale registration statement on Form S-3 with the SEC within 30 calendar days of October 29, 2025, to register the resale of shares underlying the Inducement Warrants.
• Use commercially reasonable efforts to cause the resale registration statement to become effective within 60 calendar days (or 90 days if full SEC review) of October 29, 2025.
• Hold a special meeting of stockholders on or prior to 75 days after October 29, 2025, to obtain Shareholder Approval for the issuance of shares underlying the Inducement Warrants.
• If Shareholder Approval is not obtained at the first meeting, call a meeting every 90 days thereafter until approval is secured or warrants are no longer outstanding.
• Apply to list or quote all of the New Warrant Shares on the Nasdaq Capital Market and promptly secure their listing.

Key Dates

Recommendation

The capital raise of $4.2 million provides immediate financial stability and is a positive development. However, the significant potential dilution from the issuance of new warrants (250% of exercised warrants) and the reduction of exercise prices for older warrants introduce considerable uncertainty regarding future share price performance. The requirement for shareholder approval for the new warrants also adds a layer of execution risk. Investors should monitor the shareholder vote and the impact of future warrant exercises on the company's capital structure before making further investment decisions.

Keywords

Warrant exercise, Inducement offer, Capital raise, Common stock, Private placement, Creative Medical Technology Holdings Inc., CELZ, Nasdaq, Dilution, SEC filing